Fig. 3.

percentage of additional cancer cases and rate of upstaged cancers over 2020–2030 due to type of disruption, by setting and extent of disruption (12-month scenarios).

Results for the US represent the midpoint of results for the two included models (Harvard and Policy1-Cervix). Model-specific US results are included in an Appendix (Fig. A5). All Norway models reflect the recommendation that women aged 25–33y be screened with 3y cytology; all US models reflect the recommendation that women aged 21–29y be screened with 3y cytology.